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Abstract A consecutive sample of patients who were
switched from strong opioids to methadone in a period of
1 year was surveyed. QTc was assessed before switching
(T0) and after achieving adequate analgesia and an acceptable
level of adverse effects (Ts). Twenty-eight of 33 patients were
switched to methadone successfully. The mean initial metha-
done doses at T0 were 67.1 mg/day (SD ±80.2, range 12–
390). The mean QTc interval at T0 was 400 ms (SD ±30,
range 330–450). The mean QTc interval at Ts (median 5 days)
was 430 ms (SD ±26, range 390–500). The difference (7.7 %)
was significant (p <0.0005). Only two patients had a QTc of
500 ms. No serious arrhythmia was observed. At the linear
regression analysis, there was no significant association be-
tween mean opioid doses expressed as oral morphine equiv-
alents and QTc at T0 (p =0.428), nor between mean metha-
done doses and QTc at Ts (p =0.315). No age differences were
found with previous opioid doses (p =0.917), methadone
doses (p =0.613), QTc at T0 (p =0.173), QTc at Ts (p =
0.297), and final opioid–methadone conversion ratio (p =
0.064). While methadone used for opioids switching seems
to be an optimal choice to improve the opioid response in
patients poorly responsive to the previous opioid, the possible
QTc prolongation should be of concern despite not producing
clinical consequences in this group of patients. A larger num-
ber of patients should be assessed to quantify the risk of
serious arrhythmia.
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Methadone has specific pharmacokinetic and pharmacody-
namic properties which could be attractive in several pain
conditions. However, dosing of this drug can be challenging
for the practicing physicians. Despite lack of reliable
equianalgesic conversion ratios, the large interindividual var-
iability in methadone pharmacokinetics, as well as the poten-
tial for pharmacological interaction with other drugs, in a
selected setting, methadone is an invaluable drug for resolving
difficult pain conditions [19]. Early research with methadone-
maintained patients revealed that methadone fatalities occur
primarily due to respiratory arrest duringmethadone induction
and in the context of polysubstance use. Recent reports of
methadone deaths emphasize the role of methadone-related
QT prolongation, and the possibility of inducing torsades de
pointes, a potentially fatal ventricular arrhythmia [3, 22].
Recent recommendations suggest that methadone should
be used by experienced physicians [1]. For these reasons,
methadone is commonly used as a second-line drug, for
opioid substitution with remarkable advantages from the clin-
ical point of view [17, 18].
The aim of this study was to assess the QTc interval
changes in the context of opioid switching, which is the most
frequent occasion in daily practice to use methadone in ad-
vanced cancer patients unresponsive to previous opioids.
Methods
A consecutive sample of patients who were switched from
strong opioids to methadone in a period of 1 year was sur-
veyed. Informed consent and ethical committee approval were
obtained. Patients were eligible if they had cancer pain, were
receiving opioids in doses of more than 60 mg or oral
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morphine equivalents with an unfavorable opioid response,
characterized by poor pain control and/or adverse effects,
despite symptomatic therapy. Patients with a previous history
of arrhythmia or severe bradycardia were excluded. Patients
who were receiving potential drugs capable of prolonging QT
interval were recorded. The protocol of opioid switching to
methadone has been described elsewhere. Shorty, an initial
fixed ratio of 5:1 (previous opioid doses expressed as oral
morphine equivalents) is used, and then doses are modified on
the basis of the clinical response, according to a flexible
approach [15, 16]. Patients achieving adequate analgesia and
an acceptable level of adverse effects after switching were
considered at time of stabilization (Ts) when methadone doses
were considered stable and the patient ready to be discharged.
Opioid doses and methadone doses were recorded before
switching (T0) and at Ts, respectively. To determine the QTc
interval, a resting 12-lead electrocardiogram (ECG) was
performed at T0 and Ts. The QT interval was corrected for
heart rate (QTc) by a computerized system, using the Bazett
formula.
Statistics
Data were collected and analyzed by the SPSS Software 14.0
version (SPSS, Inc., Chicago, IL, US) and the Epi Info soft-
ware, version 3.2.2 (Centers for Disease Control and Preven-
tion). Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all the
items. The paired samples Student's t test was used to compare
parametric variables in the different periods. The comparison
between the mean opioid dosages and QTc at T0 and Ts was
performed by the simple linear regression analysis. All
P values were two-sided and P values less than 0.05 were
considered to indicate statistical significance.
Results
Thirty-three patients were surveyed in the period taken into
consideration. Four patients did not achieve dose stabilization
and were further switched to other opioids. In one patient, data
were incomplete. Twenty-eight patients who were switched to
methadone successfully had complete data and were sur-
veyed. The mean age was 63.5 years (SD ±8.1), and 18 were
males. The most frequent cancer diagnoses were in a rank
order: lung 11 (39.3 %), breast 4 (14.3 %), urogenital 4
(14.3 %), and others 9 (32.1 %). The mean opioid doses at
T0 were 310.9 mg/day (SD ±367.1, range 20–1,920),
expressed in oral morphine equivalents. The mean initial
methadone doses at T0 were 67.1 mg/day (SD ±80.2, range
12–390), with 11 patients (39 %) receiving methadone doses
of ≥60 mg/day. The final conversion ratio between the previ-
ous opioid, expressed as oral morphine equivalents, and
methadone was 5.6 (SD ±3.4, range 1.1–14.0). Ts were
achieved within a median of 5 days.
The mean QTc interval at T0 was 400 ms (SD ±30, range
330–450). The mean QTc interval at Ts was 430 ms (SD ±26,
range 390–500). The difference (7.7 %) was significant (p <
0.0005). Ten male patients had a QTc ≥430 ms after metha-
done treatment, although two of them previously had a QTc
≥430 ms before switching. No female had any QTc prolonga-
tion. Only two patients had a QTc of 500 ms. At the linear
regression analysis, there was no significant association be-
tween mean opioid doses, expressed as oral morphine equiv-
alents, and QTc at T0 (p =0.428), nor between mean metha-
done doses and QTc at Ts (p =0.315).
Eleven patients were over 65 years. The mean opioid
doses, expressed as oral morphine equivalents, at T0 were
320 mg/day (SD ±234, range 90–900). The mean initial
methadone doses at T0 were 57.3 mg/day (SD ±55, range
15–210). The final conversion ratio between oral morphine
equivalents of the previous opioid and methadone was 7 (SD
±3.7, range 1.5–14). The mean QTc interval at T0 was 409 ms
(SD ±25, range 360–450). The mean QTc interval at Ts was
436 ms (SD ±24, range 420–500). The difference (6.6 %) was
significant (p =0.015). No age differences were found with
previous opioid doses (p =0.917), methadone doses (p =
0.613), QTc at T0 (p =0.173), QTc at Ts (p =0.297), and final
opioid–methadone conversion ratio (p =0.064).
Six patients were receiving drugs which potentially pro-
long QT interval, including haloperidol (two patients), ami-
triptyline (one patient), doxepin (one patient), ciprofloxacin
(one patient), levofloxacin (one patient). The mean QTc inter-
val variations did not differ from those reported in the other
patients (p =0.1).
Discussion
An extensive literature search identified over 160 drugs capa-
ble of prolonging QT interval [27]. Concerns about a possible
association between very high dose methadone and torsades
de points have been raised in recent years. A retrospective
case series has shown that patients onmethadone maintenance
treatment who developed torsades de points were receiving
mean doses of 397 mg and their mean QTc was 615 ms,
although 14 patients had other risk factors for arrhythmia
[8]. Since then, a growing body of evidence suggested an
association between methadone and QTc prolongation and
torsades de pointes in methadone users for maintenance.
Many occurred in the setting of additional contributing factors
and were associated with relatively high doses of methadone
[11]. Proposed threshold for QTc interval prolongation have
been set as low as 430 ms for men and 470 ms for women or a
gender-independent threshold of 450 ms [11]. By using a
modeling and simulation approach, pooled data obtained from
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five clinical trials in patients on methadone maintenance treat-
ment reported that with an increase of more than 20 ms or a
QTc more than 500 ms, the incidence of torsades de points is
expected to increase. Furthermore, methadone doses of more
than 120 mg/day can increase the mean QTc interval by 15 ms
[4]. However, other than methadone pharmacokinetics, other
factors possibly influencing QTc intervals were not examined
in this model. How often patients treated with methadone
develop arrhythmia is not clear [11], also because prospective
data are limited. In a recent cross-sectional study, QTc prolon-
gation prevalence was 18.1 % with no “clinically significant”
QTc prolongation of >500 ms or torsades de pointes known to
be present [15]. Similarly, while most methadone-treated pa-
tients develop QTc prolongation, however, critical QTc pro-
longation (exceeding 500 ms or increases exceeding 60 ms)
occurred infrequently [10].
The mean doses used for chronic pain appears to be
much lower than the doses used to treat opioid dependency.
In patients with non-malignant pain, minor increases and
fluctuations in QTc during a prolonged treatment with meth-
adone in doses of less than 100 mg/day were found [5]. In a
mixed population of patients with chronic pain or mainte-
nance therapy receiving methadone with median doses of
110 mg/day, 33 % of patients had QTc prolongation related
to methadone dose, but no patient had a QTc longer than
500 ms [2].
Literature on cancer patients is poor. QTc intervals for
every ECG performed on and off intravenous methadone
therapy in 42 patients receiving mean doses of 408 mg/day,
were compared with a separate group of 33 patients treated
with mean doses of 235 mg/day of intravenous morphine. The
mean differences in QTc intervals on and off methadone were
consistent, 41.7 ms, while for morphine was 9 ms. A signif-
icant relationship between changes in QTc and methadone
dose was found. This finding was attributed to methadone in
combination with its preservative chlorobutanol, which pro-
duced a synergistic action on cardiac K + current in a separate
experimental study performed on human embryonic cells [7].
In a retrospective analysis of 56 available patients receiving
median doses of 30 mg/day of methadone, none of them had a
QTc >500 ms after methadone therapy [24]. In a more recent
study, patients started on methadone for pain management
either as initial opioid or as a switch from other opioids was
assessed at baseline and the 2 and 4 weeks after. Mean doses
were relatively low 2 weeks after (median dose 23 mg/day,
range 3–90 mg), and it is likely that most patients were
initiated with methadone. At baseline prior to initiation of
methadone, 28 % of patients had QTc prolongation. Signifi-
cant increases in QTc occurred in 1.6 % of patients with no
clinical evidence of dangerous arrhythmias [25].
In this study, we recorded the QTc changes of patients who
were receiving other opioids unsuccessfully, generally with
consistent doses (more than 300 mg/day of oral morphine
equivalents on average), and then after patients achieved a
clinical stabilization with regular doses of methadone which
provided adequate pain relief and symptom intensity, com-
monly considered as a successful switching. Eleven patients
(38%) received ≥60mg ofmethadone/day, which is a relevant
dose of methadone (corresponding to 300 mg/day of oral
morphine equivalents, according to conversion ratio used),
and two patients had QTs values of 500 ms, without any
clinical consequence. Of interest, QTc was not related to
methadone doses, confirming data recorded in methadone
maintenance treatment patients [12, 23, 26], at least in the
dose range similar to that reported in this study. This is in
contrast with other observations [9, 13, 14]. Indeed, no epi-
sodes of arrhythmia were observed. The use of concomitant
drugs, potentially influencing the duration of QTc, was un-
eventful, although the low number of patients cannot allow
drawing a definite conclusion.
Drugs with risk of torsades de pointes are divided in three
categories: risk, possible risk, and conditional risk. Some of
these drugs, such as haloperidol, are commonly given to
palliative care patients, for symptommanagement or to reduce
the opioid-related adverse effects, particularly to assist opioid
switching, and are rarely discontinued. Of interest, haloperi-
dol, like methadone, belongs to the list of drugs with risk of
torsades de pointes, while the other drugs, amitriptyline,
doxepin, ciprofloxacin, and levofloxacin are considered as
substances with a possible risk [20].
Switching to methadone was effective in most cases and
the initial conversion ratio did not change significantly after
achieving stable dose, despite the large individual variations.
Interestingly, data were similar also in older patients who
should be considered at higher risk.
This study has some limitations. Definite conclusion can-
not be drawn from a relatively low number of patients. This
sample, however, was prospectively assessed in 1 year and
reflects the activity of a high volume unit where opioid
switching is frequently performed. In a retrospective analysis
of medical records of 345 inpatients undergoing opioid
switching tomethadone no patient presented clinically evident
arrhythmias [16]. A single ECG was performed once the
patient was receiving stable and effective doses of methadone.
While fluctuation of the QT interval found at a stable dose of
methadone suggests that a single normal ECG does not guar-
antee that the patient is not at risk of ventricular arrhythmias
[21], no specific timing has been conceived to exclude the risk
and any ECG performed at any time would not predict any-
thing [6]. Means of multiple ECG paradoxically could limit
the ability of preventing the risk. Patients were re-evaluated
about 5 days after switching when the clinical condition was
considered optimal and the patients ready to be discharged.
From the practical point of view, further analysis in time of
QTc was considered difficult. QTc increases seem to be more
likely after 6–12 months of methadone therapy [14, 23], so
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that the problem could be of interest in cancer patients with
prolonged survival.
Expert recommendations suggest performing ECG in pa-
tients receiving or starting methadone, particularly, those with
multiple risk factors for QT prolongation. These panel recom-
mendations were not intended to supplant clinical judgment
and may not apply to patients with difficult cancer pain [11]
which is the population examined in this survey. In the broader
context of risks and benefits of cancer patients, methadone
remains an invaluable drug in the armamentarium of palliative
care physicians, and the potential risk should not deter physi-
cians from using it. In any case, patients receiving high dose of
opioids unsuccessfully, who require an opioid switching to
methadone, are commonly hospitalized to limit the high var-
iability in response to methadone. In conclusion, switching to
methadone may produce a QT prolongation and require ap-
propriate monitoring. Clinical consequences as relevant ar-
rhythmia are unlikely in the clinical setting of opioid
switching. This data should be confirmed in studies with
larger number of patients and in different settings.
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